Form 4: Syndax CEO Metzger Exercises Options, Sells Shares

Syndax Pharmaceuticals CEO Michael A. Metzger exercised stock options and subsequently sold an equal number of shares under a pre-arranged 10b5-1 plan.

Summary

• Michael A. Metzger, Chief Executive Officer and Director of Syndax Pharmaceuticals Inc. (SNDX), executed a series of transactions on September 8, 2025.
• Metzger acquired 157,307 shares of common stock by exercising stock options at a price of $10.90 per share.
• Concurrently, he sold 157,307 shares of common stock at an average price of $16.4139 per share, with individual sale prices ranging from $16.21 to $17.06.
• These transactions were conducted under a Rule 10b5-1 trading plan, specifically for equity grants with expiration dates prior to September 10, 2025.
• Following these transactions, Metzger directly owns 298,661 shares of common stock.
• He retains 1,319,634 vested and immediately exercisable stock options, and 651,241 unvested stock options.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-planned insider transaction where the CEO exercised options and sold shares for a profit. While it's an insider sale, the existence of a 10b5-1 plan and the executive's continued substantial equity holdings mitigate negative sentiment. It reflects a standard liquidity event for an executive.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned sale and not a reaction to recent events or non-public information.
• The sale price of $16.4139 per share is significantly higher than the exercise price of $10.90, indicating a profitable transaction for the executive.
• The executive still holds a substantial number of vested and unvested options (1,319,634 vested, 651,241 unvested), maintaining significant equity interest in the company.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, as it reduces the executive's direct share ownership.

Future Outlook

NA

Management Comments

• The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person solely covering equity grants with expiration dates prior to September 10, 2025.

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by a key executive could be interpreted in various ways, but the pre-planned nature (10b5-1) and the executive's continued significant equity holdings suggest it's a routine liquidity event rather than a loss of confidence.
• Employees: No direct impact on employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled insider transaction by the CEO, involving the exercise of options and subsequent sale of shares for a profit. Such transactions are common for executives managing their equity compensation and liquidity. The sale was conducted under a Rule 10b5-1 plan, indicating it was not based on new, non-public information. The executive retains a substantial number of vested and unvested options, maintaining significant alignment with shareholder interests. Therefore, this filing alone does not provide a basis for a change in investment thesis, warranting a 'hold' recommendation.

Keywords

Syndax Pharmaceuticals, SNDX, Michael A. Metzger, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Equity Sales, CEO, Director